Vascular Endothelial Growth Factor Inhibitor [EPC]

136753 reported adverse events

Drugs of this class: RANIBIZUMAB AFLIBERCEPT BEVACIZUMAB BEVACIZUMAB-AWWB BEVACIZUMAB-BVZR BEVACIZUMAB-MALY RANIBIZUMAB-EQRN RANIBIZUMAB-NUNA ZIV-AFLIBERCEPT

These side effects are most commonly reported by patients taking drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class:

# Side effect Count
0 DEATH 21139
1 OFF LABEL USE 8616
2 DIARRHOEA 6263
3 DISEASE PROGRESSION 5896
4 NAUSEA 5652
5 FATIGUE 5297
6 HYPERTENSION 5196
7 VOMITING 4404
8 VISUAL ACUITY REDUCED 3851
9 DRUG INEFFECTIVE 3602
See all common reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]

Drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RETINAL PIGMENT EPITHELIAL TEAR 468 0.8225
1 POLYPOIDAL CHOROIDAL VASCULOPATHY 224 0.8058
2 BACTERIAL ENDOPHTHALMITIS 50 0.7463
3 PSEUDOENDOPHTHALMITIS 56 0.7179
4 NON-INFECTIOUS ENDOPHTHALMITIS 412 0.6592
5 DIABETIC RETINAL OEDEMA 255 0.6538
6 SUBRETINAL FIBROSIS 95 0.6209
7 DETACHMENT OF RETINAL PIGMENT EPITHELIUM 435 0.6179
8 RETINAL THICKENING 84 0.6176
9 CHOROIDAL NEOVASCULARISATION 366 0.5932
See all enriched reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]